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Abstract
Introduction Immunization with glucose-6-phosphate
isomerase (GPI) induces severe arthritis in DBA/1 mice. The
present study was designed to identify the cytokines and co-
stimulatory molecules involved in the development of GPI-
induced arthritis.
Methods Arthritis was induced in DBA/1 mice with 300 μg
human recombinant GPI. CD4+ T cells and antigen-presenting
cells from splenocytes of arthritic mice were cultured in the
presence of GPI. Tumor necrosis factor (TNF)-α, IFN-γ, IL-2, IL-
4, IL-5, IL-6, IL-10, and IL-12 levels were assessed using
cytometric bead array. Monoclonal antibodies to TNF-α, IFN-γ,
IL-12, CD40L, inducible co-stimulator (ICOS), and cytotoxic T-
lymphocyte antigen 4 immunoglobulin (CTLA-4Ig) were used to
block TNF-α and IFN-γ production, examine clinical index in mice
with GPI-induced arthritis, and determine anti-GPI antibody
production.
Results Large amounts of TNF-α and IFN-γ and small amounts
of IL-2 and IL-6 were produced by splenocytes from mice with
GPI-induced arthritis. Anti-TNF-α mAbs and CTLA-4Ig
suppressed TNF-α production, whereas anti-IFN-γ mAbs, anti-
IL-12 mAbs, and CTLA-4 Ig inhibited IFN-γ production. A single
injection of anti-TNF-α and anti-IL-6 mAbs and two injections of
CTLA-4Ig reduced the severity of arthritis in mice, whereas
injections of anti-IFN-γ and anti-IL-12 mAbs tended to
exacerbate arthritis. Therapeutic efficacy tended to correlate
with reduction in anti-GPI antibodies.
Conclusion TNF-α and IL-6 play an important role in GPI-
induced arthritis, whereas IFN-γ a p p e a r s  t o  f u n c t i o n  a s  a
regulator of arthritis. Because the therapeutic effects of the
tested molecules used in this study are similar to those in
patients with rheumatoid arthritis, GPI-induced arthritis appears
to be a suitable tool with which to examine the effect of various
therapies on rheumatoid arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder
with variable disease outcome, and is characterized by a pol-
yarticular inflammatory process of unknown etiology. The
prognosis for RA patients has improved significantly in recent
years following the introduction of tumor necrosis factor
(TNF)-α antagonists [1]. Despite the increased popularity of
this form of therapy, its precise mechanism of action in RA
remains unclear.
Collagen-induced arthritis (CIA) is widely used as an experi-
mental model to evaluate the effects of therapeutic agents on
human RA. The effects of various anti-cytokine mAbs have
been examined in this model, especially after the onset of
AP = alkaline phosphatase; APC = antigen-presenting cell; CBA = cytometric bead array; CIA = collagen-induced arthritis; CTLA-4Ig = cytotoxic T-
lymphocyte antigen 4 immunoglobulin; GPI = glucose-6-phosphate isomerase; GST = glutathione S-transferase; hGPI = recombinant GPI-GST 
fusion; ICOS = inducible co-stimulator; IFN = interferon; IL = interleukin; mAb = monoclonal antibody; PBS = phosphate-buffered saline; RA = rheu-
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clinical arthritis. Previous studies reported that anti-IL-1 and
anti-IL-12 mAbs significantly suppressed arthritis, whereas
anti-TNF-α therapy had little effect in this model [2-5], and
blockade of IL-6 had no effect in established CIA [6], indicat-
ing different therapeutic mechanisms in RA [7,8].
The ubiquitously expressed self-antigen glucose-6-phosphate
isomerase (GPI) was identified as an arthritogenic target in the
K/B × N T-cell receptor transgenic mouse model [9,10].
Recently, immunization with human GPI was reported to pro-
voke acute, severe arthritis in DBA/1 mice (GPI-induced arthri-
tis), supporting the notion that T-cell and B-cell responses to
GPI play a crucial role in the development of arthritis [11,12].
We recently described the presence of GPI-reactive T cells in
HLA-DRB1*0405/*0901-positive patients with RA who har-
bored anti-GPI antibodies, a finding that emphasizes the path-
ogenic role of antigen-specific T cells in anti-GPI antibody-
positive patients [13].
The aim of the present study was to determine the mechanism
of antigen-specific arthritis. For this purpose, we analyzed the
role of several cytokines and co-stimulatory molecules in GPI-
induced arthritis after clinical onset. The production of TNF-α
by cultured splenocytes was increased, and anti-TNF-α mAb
and cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA-
4Ig) efficiently suppressed TNF-α production by splenocytes.
Furthermore, a single injection of anti-TNF-α mAb and two
injections (on days 8 and 12, or days 12 and 16) of CTLA-4Ig
markedly reduced the severity of the disease. In contrast, nei-
ther anti-IFN-γ nor anti-IL-12 mAb altered the course of the dis-
ease. Surprisingly, a single injection of anti-IL-6 mAb resulted
in cure of arthritis. Further analyses showed the presence of
high serum TNF-α and IL-6 levels, but not IFN-γ and IL-1β, in
arthritic mice. Moreover, effective treatment with these agents
tended to reduce anti-GPI antibody production. These find-
ings suggest that TNF-α and IL-6 play important roles in acute-
onset arthritis in GPI-immunized mice. These results point to
the potential roles played by these cytokines in the patho-
genicity of human RA, and suggest that therapeutic strategies
directed against TNF-α and IL-6 might be fruitful in RA.
Materials and methods
GPI-induced arthritis in DBA/1 mice
Male DBA/1 mice (aged 6 to 8 weeks) were obtained from
Charles River (Yokohama, Japan). Recombinant human GPI
was prepared as described previously [14]. Mice were immu-
nized by intradermal injection of 300 μg recombinant human
GPI-glutathione S-transferase (GST) fusion protein (hGPI) in
emulsified complete Freund's adjuvant (Difco, Detroit, MI,
USA). Control mice were immunized with 300 μg GST in com-
plete Freund's adjuvant. The experimental protocol was
approved by the Ethics Review Committee for Animal Experi-
mentation of Tsukuba University School of Medicine. Arthritic
animals were clinically assessed and ankle thickness
recorded. We used the following arthritis scoring system to
evaluate the disease state (clinical index): 0 = no evidence of
inflammation, 1 = subtle inflammation or localized edema, 2 =
easily identified swelling but localized to either dorsal or ven-
tral surface of paws, and score 3 = swelling on all aspects of
paws. All four limbs were evaluated using a constant tension
caliper and graded, yielding a maximum possible score of 12
per mouse.
Histological assessment of arthritis
At the indicated time points, the ankles of the mice were
removed, fixed, decalcified and paraffin-embedded. Sections
(5 μm) were stained with hematoxylin and eosin, and evaluated
for histologic changes indicating inflammation, pannus forma-
tion, and cartilage and bone damage.
Preparation of splenocytes and cytometric bead array
Spleens were dissected from immunized DBA/1 or B6 mice
(on day 8 after immunization) and immediately immersed in
phosphate-buffered saline (PBS; Gibco, Grand Island, NY,
USA). Single-cell suspensions were prepared. Red blood cells
were lysed by incubation of the suspension in NH4Cl (0.83%
in 0.01 mol/l Tris-HCl [pH 7.2]). The number of splenocytes
was then counted, centrifuged again, and resuspended in
RPMI (Gibco, Grand Island, NY, USA). For culture, we used
RPMI supplemented with 100 μg/ml streptomycin, 100 U/ml
penicillin, 10% fetal bovine serum, and 50 μM 2-mercaptoeth-
anol. After counting the cells, the medium was added to make
the final concentration 2.5 × 106/ml. Next, CD4+ T cells were
isolated by positive selection with anti-mouse CD4+ antibody
(T cell isolation kit; Miltenyi Biotec, Bergisch Gladbach, Ger-
many). The labeled cells were then passed through separation
columns (MiniMACS columns; Miltenyi Biotec). The cells con-
tained more than 97% CD4+ T cells. T-depleted spleen cells
were treated with 50 μg/ml mitomycin C (Kyowa Hakko
Kogyo, Tokyo, Japan) for 30 minutes at 37°C and were used
as antigen-presenting cells (APCs).
CD4+ T cells (1 × 106 cells/ml) were stimulated with 5 μg/ml
GPI (or GST) and APCs (2 × 105 cells/ml) in 1 ml volume in
48-well culture plates (Nunc) for 12 hours. The culture super-
natants were collected and cell-free samples were stored at -
30°C until the cytokine assay. The concentrations of TNF-α,
IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-12p70 were measured
using cytometric bead array (CBA) with a series of anti-
cytokine mAb-coated beads and PE-conjugated anti-cytokine
mAbs, followed by Epics XL flow cytometric analysis (Beck-
man-Coulter Electronics, Fullerton, CA, USA), using the CBA
kit (BD Bioscience, San Jose, CA, USA) and software (BD).
Antibodies used for in vitro and in vivo studies
We used commercially available anti-TNF-α mAb (eBio-
science, San Diego, CA, USA; 10 μg/ml), anti-IFN-γ mAb (BD
Biosciences; 1 μg/ml), and anti-IL-12 mAb (BD; 0.3 μg/ml) to
neutralize the respective cytokines. These concentrations
were selected based on more than 80% blockade of theAvailable online http://arthritis-research.com/content/10/3/R66
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respective cytokine. CTLA-4Ig (BD; 1 μg/ml), anti-inducible
co-stimulator (ICOS) mAb (BD; 0.5 μg/ml), and anti-CD40L
mAb (BD; 1 μg/ml) were used to block co-stimulatory path-
ways. As a control antibody, we used the same amount of rat
IgG1 isotype control (R&D Systems, Minneapolis, MN, USA).
Inhibition study was conducted by adding the above concen-
tration at the start of culture. Three independent experiments
were performed.
On day 8 after the onset of arthritis, each mouse received a
single injection of 100 μg of anti-TNF-α mAb, anti-IL-12 mAb,
anti-IFN-γ mAb or anti-IL-6 mAb. A single injection of anti-IL-6
mAb on day 14 was also administered. On the other hand, two
injections of 100 μg CTLA-4Ig were administered on days 8
and 12, or on days 12 and 16 after the onset of arthritis.
Measurement of serum levels of cytokines and anti-GPI 
antibodies
Serum samples were collected at the indicated time points.
The serum levels of TNF-α, IL-6, IL-1β and IFN-γ were deter-
mined with the respective enzyme-linked immunosorbent
assay kits (BD). To detect the levels of anti-GPI antibodies, we
used hGPI and GST at 5 μg/ml (diluted in PBS) to coat micro-
titer plates (12 hours, 4°C). After washing twice with washing
buffer (0.05% Tween 20 in PBS), Block Ace (diluted 1/4 in 1
× PBS; Dainippon Pharmaceuticals, Osaka, Japan) was used
for saturation (2 hours at room temperature). After two
washes, sera (diluted 1/500) were added and the plates incu-
bated for 2 hours at room temperature. After washing, alkaline
phosphatase (AP)-conjugated anti-mouse IgG (Fc-fragment
specific; Jackson Immunoresearch Laboratories, West Grove,
PA, USA) was added to the plate (dilution 1/5,000, 1 hour,
room temperature). After three washes, color was developed
with AP reaction solution (containing 9.6% diethanolamine
and 0.25 mmol/l MgCl2 [pH 9.8]) with AP substrate tablets
(Sigma Chemical Co., St. Louis, MO, USA; one AP tablet per
5 ml AP reaction solution). Plates were incubated for 30 min-
utes at room temperature and the optical density was meas-
ured by plate spectrophotometry at 405 nm. Determinations
were conducted in triplicate, and standardized between exper-
iments by reference to a highly positive mouse anti-GPI serum.
The primary reading was processed by subtracting optical
density readings of control wells (coated with GST for hGPI).
Statistical analysis
All data were expressed as mean ± standard error of the mean.
Differences between groups were examined for statistical sig-
nificance by using Mann-Whitney's U test. P < 0.05 denoted
the presence of a statistically significant difference.
Results
Induction of arthritis in mice immunized by recombinant 
human GPI
To investigate whether our own GPI immunization procedure
can induce arthritis, we immunized DBA/1 mice using human
recombinant GPI prepared in our laboratories. As reported
previously [9,10,15], all mice developed arthritis after immuni-
zation with 300 μg recombinant GPI. Arthritis appeared at day
8, and severe arthritis was noted at day 14, with maximum
ankle swelling on day 14 (data not shown). GST immunization
did not induce apparent arthritis (data not shown).
GPI induces production of TNF-α and IFN-γ by spleen 
cells at onset of arthritis
To identify the dominant cytokines at the onset of antigen-
induced arthritis (day 8), we established the CBA array system
using spleen CD4+ T cells plus mitomycin-treated APCs cul-
tured in GPI. In this system, treatment of APCs with mitomycin
is designed to kill autoreactive APCs. The results demon-
strated the production of large amounts of TNF-α and IFN-γ by
the spleen of arthritic mice (Figure 1). In contrast, cells cul-
tured with control antigen (GST) instead of GPI did not pro-
duce these cytokines (Figure 1). APC plus antigen alone
produced such amounts of cytokines. Very low but detectable
levels of IL-2 and IL-6 were produced, but almost no T-helper-
2 type cytokines (such as IL-4, IL-5, and IL-10) were detected
(Figure 1). These results indicate that exposure to the GPI anti-
gen results in induction of TNF-α and IFN-γ by immunocytes,
and suggest that these cytokines could play a crucial role in
the induction of arthritis in GPI-induced mice.
Anti-cytokine mAbs and co-stimulator blockade inhibit 
in vitro cytokine production
To delineate the separate contributions of TNF-α and IFN-γ,
we performed blocking experiments using neutralizing mAbs
for anti-TNF-α, IFN-γ, and IL-12 using the CBA array system.
TNF-α production was inhibited by anti-TNF mAb (64.7 ±
Figure 1
GPI-induced TNF-α and IFN-γ production from arthritic splenocytes in  vitro GPI-induced TNF-α and IFN-γ production from arthritic splenocytes in 
vitro. Spleens were removed from glucose-6-phosphate isomerase 
(GPI)-immunized DBA/1 mice (on day 8 after immunization), and then 
single-cell suspensions were prepared. MACS separated CD4+ T cells 
(1 × 106 cells/ml) were stimulated with 5 μg/ml GPI (or glutathione S-
transferase [GST]) and antigen-presenting cells (APCs; 2 × 105 cells/
ml, mitomycin treated) for 12 hours. The culture supernatants were col-
lected and concentrations of tumor necrosis factor (TNF)-α, IFN-γ, IL-2, 
IL-4, IL-5, IL-6, IL-10, and IL-12p70 were measured by cytometric bead 
array. Data were averages of three independent experiments. Error bars 
represent ± standard error. *P < 0.05, by Mann-Whitney U-test.Arthritis Research & Therapy    Vol 10 No 3    Matsumoto et al.
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2.7%; Figure 2a), but not by anti-IL-12 mAb (0%; Figure 2a).
On the other hand, IFN-γ production was inhibited by anti-IFN-
γ mAb (82.5 ± 1.2%; Figure 2b) as well as by anti IL-12 mAb
(67.5 ± 2.5%; Figure 2b), and weakly by anti-TNF-α mAb
(17.2 ± 9.2%; Figure 2b). These results suggest that TNF-α
production is not regulated by IFN-γ, although IFN-γ is partially
regulated by TNF-α.
To determine the effect of co-stimulatory molecules in estab-
lished arthritis, we conducted the same in vitro experiments by
using CTLA-4Ig, anti-ICOS, and anti-CD40L mAbs. CTLA-4Ig
suppressed TNF-α (18 ± 2.1%; Figure 2c), and IFN-γ (42.9 ±
2.1%; Figure 2d) production, but not anti-ICOS or anti-CD40L
mAb. These findings suggest that the antigen-induced
cytokines are mainly driven by CD28/B7-1,2 co-stimulator.
Treatment of GPI-induced arthritis with anti-TNF-α mAb
To identify the pathogenic cytokine that can provoke the onset
of arthritis, we conducted in vivo experiments using neutraliz-
ing mAbs. A single injection of 100 μg of anti-TNF-α mAb at
day 8 ameliorated the disease (Figure 3a). In contrast, injec-
tion of the same dose of anti-IFN-γ or anti-IL-12 mAb had no
such effect on the course of the disease, but rather tended to
exacerbate the arthritis (Figure 3b). Histopathological exami-
nation of the joints of treated mice showed a clear therapeutic
effect for anti-TNF-α mAb (Figure 3f, on day 21) as compared
with that of control antibody (Figure 3g, on day 21). These
results suggest that TNF-α blockade has clear therapeutic
effect in GPI-induced model, irrespective of the minor role of
'conventional' T-helper-1 autoimmunity.
Figure 2
In vitro inhibition assay of GPI-induced TNF-α and IFN-γ production using anti-cytokine mAbs or anti-co-stimulators In vitro inhibition assay of GPI-induced TNF-α and IFN-γ production using anti-cytokine mAbs or anti-co-stimulators. High amounts of tumor necrosis 
factor (TNF)-α and IFN-γ were produced by splenocytes cultured with glucose-6-phosphate isomerase (GPI). Thus, we used anti-TNF-α mAb (10 
μg/ml), anti-IFN-γ mAb (1 μg/ml), and anti-IL-12 mAb (0.3 μg/ml) to neutralize these cytokines in the in vitro cytometric bead array system. Inhibition 
study was conducted by adding the above concentrations at commencement of culture. These concentrations were calculated to produce more 
than 80% blockade of these cytokines. The percentage inhibition rate is calculated by cytokine production with this system: 100 – ([cytokine mAb – 
control antibody]/control antibody). The inhibition rate of (a) TNFα and (b) IFN-γ are shown. Cytotoxic T-lymphocyte antigen 4 immunoglobulin 
(CTLA-4Ig; 1 μg/ml), anti-inducible co-stimulator (ICOS) mAb (0.5 μg/ml), and anti-CD40L mAb (1 μg/ml) were also used to block co-stimulatory 
pathways, and the inhibition rate of (c) TNF-α and (d) IFN-γ are shown. Three independent experiments were performed. Data are expressed as 
mean ± standard error of the mean.Available online http://arthritis-research.com/content/10/3/R66
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Figure 3
Therapeutic effect of anti-TNF mAb, CTLA-4Ig, and anti-IL-6 mAb in GPI-induced arthritis Therapeutic effect of anti-TNF mAb, CTLA-4Ig, and anti-IL-6 mAb in GPI-induced arthritis. Glucose-6-phosphate isomerase (GPI)-immunized mice 
were treated with (a) anti-tumor necrosis factor (TNF)-α mAb; (b) anti-IFN-γ mAb or anti-IL-12 mAb; (c) cytotoxic T-lymphocyte antigen 4 immu-
noglobulin (CTLA-4Ig; on days 8 and 12); (d) CTLA-4Ig (on days 12 and 16); and (e) or anti-IL-6 mAb just after the onset of arthritis (on day 8, on 
days 8 and 12, or days 12 and 16; arrow). The mean clinical index (± standard error) was examined throughout the study. *P < 0.05, **P < 0.01, by 
Mann-Whitney's U test. n = 6 mice in each group. Hematoxylin and eosin staining at day 21 (×40) is also shown: (f) anti-TNF-α mAb, (g) control 
antibody, and (h) CTLA-4Ig (on days 8 and 12).Arthritis Research & Therapy    Vol 10 No 3    Matsumoto et al.
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Treatment of GPI-induced arthritis with CTLA-4Ig and 
anti-IL-6 mAb
To investigate the effect of CTLA-4Ig in vivo, we treated
arthritic mice with CTLA-4Ig on days 8 and 12, or on days 12
and 14. A marked improvement was seen after the second
treatment (on days 8 and 12), probably because of a reduc-
tion in effector T cells at that stage (Figure 4c, and hematox-
ylin and eosin staining on day 21 in Figure 4h). Moreover, if
we admininstered treatment on days 12 and 16, clear thera-
peutic efficacy was observed after the first treatment. This
finding suggests that CTLA-4Ig is also therapeutically potent,
especially on day 12, in mice with GPI-induced arthritis.
IL-6 is also an important cytokine in arthritis, and it is consid-
ered a promising target for the treatment of RA [7,8]. Serum
IL-6 concentrations were elevated in arthritic mice, especially
during the disease effector phase (Figure 4). In the next step,
we assessed the effect of IL-6 blockade in mice with GPI-
induced arthritis. Surprisingly, anti-IL-6 treatment on day 8
resulted in improvement in the clinical index (Figure 3e),
although treatment on day 14 had no effect on the course of
the disease (data not shown), suggesting that IL-6 is also
pathologically crucial in the early effector phase in arthritis.
Role of various inflammatory cytokines in GPI-induced 
arthritis
To determine the effects of inflammatory cytokines during the
effector phase of arthritis, we measured the serum concen-
trations of TNF-α, IL-6, IL-1β, and IFN-γ at days 0, 7, 14, and
28 in DBA/1 mice after GPI immunization. Serum TNF-α con-
centration was upregulated at disease onset (day 7), but
gradually decreased to the basal level by day 28 (Figure 4).
On the other hand, serum IL-6 concentration was upregu-
lated gradually, especially during the disease effector phase
(days 7 and 14; Figure 4). In contrast, serum IL-1β and IFN-
γ concentrations were persistently low and below the detec-
tion limit (4 pg/ml) in GPI-induced mice throughout the study
(Figure 4). These findings suggest a systemic TNF-α/IL-6
imbalance in arthritic mice.
Effective treatments tend to alter anti-GPI antibody 
production
Anti-GPI antibodies have potent arthritogenic capacity in K/
B × N mice. However, anti-GPI antibodies from mice with
GPI-induced arthritis do not solely cause arthritis (Schubert
and coworkers [11] and our preliminary observations). In
GPI-induced arthritis, IgG and C3 are co-localized on the
articular surface of arthritic joints (Tanaka and coworkers,
unpublished data). Accordingly, we compared the effects of
anti-cytokine mAbs, immunomodulatory molecule CTLA-4Ig,
and control immunoglobulin on the production of anti-GPI
antibodies in mice with GPI-induced arthritis. The antigen
was injected on day 8, and then sera were collected on day
14. As shown in Figure 5, anti-TNF-α, anti-IL-6, and CTLA-
4Ig tended to suppress the production of anti-GPI antibod-
ies, whereas IL-12 mAb slightly enhanced the production of
the antibodies. These findings suggest that effective treat-
ments might also alter autoantibody production during this
phase of GPI-induced arthritis.
Figure 4
Concentration of inflammatory cytokines in serum of mice with GPI- induced arthritis Concentration of inflammatory cytokines in serum of mice with GPI-
induced arthritis. After immunization with glucose-6-phosphate isomer-
ase (GPI), serum samples were collected from GPI-induced DBA/1 
mice at the indicated time points (days 0, 7, 14, and 28). Serum con-
centrations of tumor necrosis factor (TNF)-α (solid circle), IL-6 (open 
square), IL-1β (open triangle), or IFN-γ (open diamond) were deter-
mined by enzyme-linked immunosorbent assay. Data are expressed as 
mean ± standard error. n = 3 mice in each group. *P < 0.05, by Mann-
Whitney's U-test.
Figure 5
Effective treatments tend to alter anti-GPI antibody production Effective treatments tend to alter anti-GPI antibody production. Glu-
cose-6-phosphate isomerase (GPI)-induced arthritic mice were treated 
with 100 μg anti-tumor necrosis factor (TNF)-α mAb, anti-IL-6 mAb, 
cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA-4Ig), and anti-
IL-12 mAb on day 8, and CTLA-4 Ig on day 12. Serum samples were 
collected on day 14. The titers of anti-GPI antibodies were analyzed by 
enzyme-linked immunosorbent assay. Each symbol represents a single 
animal. Data are expressed as mean ± standard deviation of optical 
density.Available online http://arthritis-research.com/content/10/3/R66
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Discussion
GPI, a ubiquitous glycolytic enzyme, is a new candidate
autoantigen in inflammatory arthritis, initially identified in K/B ×
N mice [10]. In K/B × N mice, anti-GPI antibodies solely
induce arthritis through activation of complements and Fcγ
receptors [16]. With regard to cytokine dependency, anti-
TNF-α mAb does not prevent the development of arthritis in K/
B × N mice, and IL-6 deficiency has no influence on the devel-
opment of arthritis by K/B × N serum transfer [17]. Based on
this cytokine dependency, K/B × N mice differ from patients
with RA.
Although the therapeutic effect of TNF antagonists has been
established in RA, there are few animal models of arthritis in
which TNF antagonists are confirmed as being therapeutically
beneficial. For example, in the most conventional RA models,
such as CIA, treatment with IL-1 antagonists significantly sup-
pressed arthritis, whereas TNF antagonists had minor effect
[2-4]. On the other hand, a clear therapeutic effect of anti-TNF-
α mAb was reported recently in DNaseII-type I IFN double
knockout mice [18], although this was not a genetically unal-
tered mouse. Schubert and coworkers [11] reported that con-
tinuous injections of human TNF receptor p75-IgG-Fc fusion
protein (etanercept) from days 0 to 9 completely protected
against the development of arthritis in GPI-induced arthritis. In
this regard, we demonstrated a clear therapeutic effect for
TNF antagonist in mice with GPI-induced arthritis, and the
therapeutic response correlated with the in vitro regulation of
TNF production. For example, we detected specific TNF-α-
induced molecules in spleen and joints of mice with GPI-
induced arthritis by Genechip analysis (Matsumoto and Inoue,
unpublished data). These results also indicate that the GPI-
induced arthritis model is suitable tool for studying the mech-
anisms of action of TNF-α antagonists in RA patients.
CTLA-4Ig can selectively modulate the CD80 or CD86-CD28
co-stimulatory signal required for full T-cell activation [19], and
is a promising new molecule for treatment of RA [19-21].
Although administration of CTLA-4Ig at the time of immuniza-
tion prevented the development of CIA, the therapeutic effi-
cacy has not been clearly confirmed in this model [22]. In the
present study, we demonstrated that only two injections of
CTLA-4Ig (both on days 8 and 12 or on days 12 and 16) mark-
edly prevented the development of arthritis in mice with GPI-
induced arthritis. What is the mechanism of action of CTLA-
4Ig in GPI-induced arthritis? We recently reported that anti-IL-
17 mAb is also therapeutically promising in this model [15],
and thus effector T-helper-17 dependency is much stronger
than in the CIA model. The present study showed that treat-
ment with CTLA-4Ig resulted in suppression of anti-GPI anti-
body production. Therefore, blockade of persistent T-cell
activation during the early effector phase appears therapeuti-
cally useful in GPI-induced arthritis, through inhibition of both
effector T-helper-17 cells and autoantibody production.
Like TNF-α and IL-1, IL-6 is a pleiotropic cytokine that is known
to play a role in RA, and a humanized anti-IL-6 receptor anti-
body (tocilizumab) was recently reported to be beneficial ther-
apeutically [7,8]. However, administration of IL-6 antagonist
did not produce any remedial effects when administered after
the onset of arthritis in CIA animals [6]. In the present study we
demonstrated that treatment with anti-IL-6 mAb inhibited the
development of arthritis and even after the onset of arthritis in
mice with GPI-induced arthritis. However, anti-IL-6 mAb had
no effect on day 14, even if we used 4 mg anti-IL-6 receptor
mAb [15]. Our results with the in vitro CBA assay showed that
IL-6 was not the main cytokine produced by antigen cultures.
Cultures of the same numbers of mitomycin-untreated and -
treated splenocytes with GPI showed that IL-6 was predomi-
nantly produced by whole spleen cells, indicating that mitomy-
cin-sensitive APCs, including B cells, were the major source of
IL-6 (data not shown). Another study showed that IL-6 antag-
onism on day 8 suppressed the proliferation of antigen-spe-
cific T cells and partially the development of T-helper-17 cells,
with reduced production of anti-GPI antibody [15]. Therefore,
the effectiveness by IL-6 antagonist on day 8 in GPI-induced
arthritis appears to be mediated through orchestration of
these mechanisms.
In the GPI-induced arthritis model, anti-GPI antibodies could
not induce arthritis on their own. Neither Fcγ receptor deficient
nor B-cell-deficient mice had overt arthritis [11,12], suggest-
ing that anti-GPI antibodies play an indispensable role in this
model. Recent studies identified co-localization of IgG and C3
on the articular surface of joints in GPI-induced arthritis on day
14, and production of anti-GPI antibodies was most vigorous
on day 8 (Tanaka and coworkers, unpublished data). These
results mimic those of arthritis mediated by K/B × N serum
transfer [23]. Thus, we investigated whether immunomodula-
tory molecules could alter this vigorous antigen-specific anti-
body production on day 8. Treatment of mice with CTLA-4Ig
resulted in downregulation of anti-GPI antibody production,
whereas anti-TNF-α and anti-IL-6 mAb therapy tended to
reduce these antibodies. In contrast, anti-IL-12 mAb rather
upregulated the production of anti-GPI antibodies, leading to
persistent arthritis. These findings suggest that production of
anti-GPI antibodies in the early effector phase may correlate
with the severity of arthritis in this model.
Does this model mimic human RA, especially in anti-GPI anti-
body-positive individuals? Severe forms of RA have been
described in patients with high titers of anti-GPI antibodies,
although these antibodies were also identified in a few control
individuals [14,24]. In anti-GPI antibody-positive individuals,
GPI-reactive CD4+ T cells, especially T-helper-1 type cells,
were detected among peripheral blood mononuclear cells of
RA patients with either HLA-DR 0405 or 0901 haplotype [13].
What about GPI-induced arthritis? High titers of anti-GPI anti-
bodies are present in arthritis-resistant C57BL/6 mice (H-2b)
[11,12], although the T cells of these animals exhibited weakArthritis Research & Therapy    Vol 10 No 3    Matsumoto et al.
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GPI responses compared with arthritis-susceptible DBA/1
mice (H-2q). These results indicate that anti-GPI antibodies
cannot themselves induce arthritis; it is likely that a unique H-
2 haplotype and activation of antigen-specific T cells are nec-
essary for the development of arthritis in this model. Moreover,
the effectiveness of CTLA-4Ig was clearly similar to that in
human RA. Considered together, GPI-induced arthritis seems
to be akin to human RA.
Conclusion
Because the therapeutic effects of the tested biologics used
in this study are similar to those in patients with RA, GPI-
induced arthritis is a suitable model for examining the patho-
genic mechanisms of RA and the effect of various treatments.
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